CEO Paul Brennan said, “To have surgeons of this calibre presenting such a wide variety of clinical applications demonstrates the robust nature of NovoSorb BTM compared with biologic products. We have significant opportunities before us in the market place and the presentations underline our sales push in the US”
CEO Paul Brennan said, “To have surgeons of this calibre...
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.29 |
Change
-0.010(0.43%) |
Mkt cap ! $1.580B | |||
| Open | High | Low | Value | Volume |
| $2.33 | $2.34 | $2.24 | $2.151M | 944.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 9090 | $2.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.29 | 15253 | 5 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| PNV (ASX) Chart |